NCT05471661View on ClinicalTrials.gov

T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 22, 2021

Primary Completion Date

May 5, 2024

Study Completion Date

May 8, 2024

Conditions
Opportunistic Fungal InfectionOpportunistic Viral InfectionBone Marrow Transplant Infection
Interventions
BIOLOGICAL

Pentavalent-specific T cells (penta-STs)

Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.

Trial Locations (2)

57010

George Papanikolaou Hospital - Gene and Cell Therapy Center- Hematology Dpt- Hematopoietic Stem Cell Transplant Center, Thessaloniki

Unknown

University General Hospital of Patras, Pátrai

All Listed Sponsors
collaborator

University General Hospital of Patras

OTHER

lead

George Papanicolaou Hospital

OTHER